Mycophenolate mofetil therapy for refractory inflammatory bowel disease

S. Palaniappan, A. C. Ford, D. Greer, S. M. Everett, D. M. Chalmers, A. T R Axon, P. J. Hamlin

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Mycophenolate mofetil (MMF) is an immunomodulatory drug, and its use in inflammatory bowel disease has previously been reported. The aim of this study was to review the Leeds Colitis Clinic experience of the safety and efficacy of MMF in treating patients with refractory Crohn's disease (CD) and ulcerative colitis (UC). This is an extension of a previously published study from our center with a longer follow-up period and approximately twice the number of patients. Methods: A retrospective analysis was performed of the records of all patients treated with MMF for inflammatory bowel disease over a 5-year period. Results: Of 70 patients identified, 67 had previously been treated with azathioprine unsuccessfully. Seventeen of the 70 patients had been successfully maintained in remission with MMF for an average duration of 33 months. Treatment with MMF was discontinued for 53 patients, 17 because of side effects and 36 because they had not responded to the treatment. Conclusions: In our series, 17 patients (24.3%) had a sustained steroid-free remission with MMF therapy. Nineteen patients (27%) experienced side effects, of which 17 (24.3% of the total group) had to discontinue therapy. An additional 36 (51.4%) required an escalation in medical therapy or surgery because of failure of the MMF therapy. MMF may have a role in the treatment of refractory inflammatory bowel disease, especially in patients who have previously failed standard therapies such as azathioprine.

Original languageEnglish
Pages (from-to)1488-1492
Number of pages5
JournalInflammatory Bowel Diseases
Volume13
Issue number12
DOIs
Publication statusPublished - Dec 2007
Externally publishedYes

Fingerprint

Mycophenolic Acid
Inflammatory Bowel Diseases
Therapeutics
Azathioprine
Colitis
Ulcerative Colitis
Crohn Disease
Steroids
Safety

Keywords

  • Crohn's disease
  • Inflammatory bowel disease
  • Mycophenolate
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Palaniappan, S., Ford, A. C., Greer, D., Everett, S. M., Chalmers, D. M., Axon, A. T. R., & Hamlin, P. J. (2007). Mycophenolate mofetil therapy for refractory inflammatory bowel disease. Inflammatory Bowel Diseases, 13(12), 1488-1492. https://doi.org/10.1002/ibd.20258

Mycophenolate mofetil therapy for refractory inflammatory bowel disease. / Palaniappan, S.; Ford, A. C.; Greer, D.; Everett, S. M.; Chalmers, D. M.; Axon, A. T R; Hamlin, P. J.

In: Inflammatory Bowel Diseases, Vol. 13, No. 12, 12.2007, p. 1488-1492.

Research output: Contribution to journalArticle

Palaniappan, S, Ford, AC, Greer, D, Everett, SM, Chalmers, DM, Axon, ATR & Hamlin, PJ 2007, 'Mycophenolate mofetil therapy for refractory inflammatory bowel disease', Inflammatory Bowel Diseases, vol. 13, no. 12, pp. 1488-1492. https://doi.org/10.1002/ibd.20258
Palaniappan S, Ford AC, Greer D, Everett SM, Chalmers DM, Axon ATR et al. Mycophenolate mofetil therapy for refractory inflammatory bowel disease. Inflammatory Bowel Diseases. 2007 Dec;13(12):1488-1492. https://doi.org/10.1002/ibd.20258
Palaniappan, S. ; Ford, A. C. ; Greer, D. ; Everett, S. M. ; Chalmers, D. M. ; Axon, A. T R ; Hamlin, P. J. / Mycophenolate mofetil therapy for refractory inflammatory bowel disease. In: Inflammatory Bowel Diseases. 2007 ; Vol. 13, No. 12. pp. 1488-1492.
@article{dacbff2ee25b4b32a859f6ff923de654,
title = "Mycophenolate mofetil therapy for refractory inflammatory bowel disease",
abstract = "Background: Mycophenolate mofetil (MMF) is an immunomodulatory drug, and its use in inflammatory bowel disease has previously been reported. The aim of this study was to review the Leeds Colitis Clinic experience of the safety and efficacy of MMF in treating patients with refractory Crohn's disease (CD) and ulcerative colitis (UC). This is an extension of a previously published study from our center with a longer follow-up period and approximately twice the number of patients. Methods: A retrospective analysis was performed of the records of all patients treated with MMF for inflammatory bowel disease over a 5-year period. Results: Of 70 patients identified, 67 had previously been treated with azathioprine unsuccessfully. Seventeen of the 70 patients had been successfully maintained in remission with MMF for an average duration of 33 months. Treatment with MMF was discontinued for 53 patients, 17 because of side effects and 36 because they had not responded to the treatment. Conclusions: In our series, 17 patients (24.3{\%}) had a sustained steroid-free remission with MMF therapy. Nineteen patients (27{\%}) experienced side effects, of which 17 (24.3{\%} of the total group) had to discontinue therapy. An additional 36 (51.4{\%}) required an escalation in medical therapy or surgery because of failure of the MMF therapy. MMF may have a role in the treatment of refractory inflammatory bowel disease, especially in patients who have previously failed standard therapies such as azathioprine.",
keywords = "Crohn's disease, Inflammatory bowel disease, Mycophenolate, Ulcerative colitis",
author = "S. Palaniappan and Ford, {A. C.} and D. Greer and Everett, {S. M.} and Chalmers, {D. M.} and Axon, {A. T R} and Hamlin, {P. J.}",
year = "2007",
month = "12",
doi = "10.1002/ibd.20258",
language = "English",
volume = "13",
pages = "1488--1492",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Mycophenolate mofetil therapy for refractory inflammatory bowel disease

AU - Palaniappan, S.

AU - Ford, A. C.

AU - Greer, D.

AU - Everett, S. M.

AU - Chalmers, D. M.

AU - Axon, A. T R

AU - Hamlin, P. J.

PY - 2007/12

Y1 - 2007/12

N2 - Background: Mycophenolate mofetil (MMF) is an immunomodulatory drug, and its use in inflammatory bowel disease has previously been reported. The aim of this study was to review the Leeds Colitis Clinic experience of the safety and efficacy of MMF in treating patients with refractory Crohn's disease (CD) and ulcerative colitis (UC). This is an extension of a previously published study from our center with a longer follow-up period and approximately twice the number of patients. Methods: A retrospective analysis was performed of the records of all patients treated with MMF for inflammatory bowel disease over a 5-year period. Results: Of 70 patients identified, 67 had previously been treated with azathioprine unsuccessfully. Seventeen of the 70 patients had been successfully maintained in remission with MMF for an average duration of 33 months. Treatment with MMF was discontinued for 53 patients, 17 because of side effects and 36 because they had not responded to the treatment. Conclusions: In our series, 17 patients (24.3%) had a sustained steroid-free remission with MMF therapy. Nineteen patients (27%) experienced side effects, of which 17 (24.3% of the total group) had to discontinue therapy. An additional 36 (51.4%) required an escalation in medical therapy or surgery because of failure of the MMF therapy. MMF may have a role in the treatment of refractory inflammatory bowel disease, especially in patients who have previously failed standard therapies such as azathioprine.

AB - Background: Mycophenolate mofetil (MMF) is an immunomodulatory drug, and its use in inflammatory bowel disease has previously been reported. The aim of this study was to review the Leeds Colitis Clinic experience of the safety and efficacy of MMF in treating patients with refractory Crohn's disease (CD) and ulcerative colitis (UC). This is an extension of a previously published study from our center with a longer follow-up period and approximately twice the number of patients. Methods: A retrospective analysis was performed of the records of all patients treated with MMF for inflammatory bowel disease over a 5-year period. Results: Of 70 patients identified, 67 had previously been treated with azathioprine unsuccessfully. Seventeen of the 70 patients had been successfully maintained in remission with MMF for an average duration of 33 months. Treatment with MMF was discontinued for 53 patients, 17 because of side effects and 36 because they had not responded to the treatment. Conclusions: In our series, 17 patients (24.3%) had a sustained steroid-free remission with MMF therapy. Nineteen patients (27%) experienced side effects, of which 17 (24.3% of the total group) had to discontinue therapy. An additional 36 (51.4%) required an escalation in medical therapy or surgery because of failure of the MMF therapy. MMF may have a role in the treatment of refractory inflammatory bowel disease, especially in patients who have previously failed standard therapies such as azathioprine.

KW - Crohn's disease

KW - Inflammatory bowel disease

KW - Mycophenolate

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=38049014413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049014413&partnerID=8YFLogxK

U2 - 10.1002/ibd.20258

DO - 10.1002/ibd.20258

M3 - Article

C2 - 17924566

AN - SCOPUS:38049014413

VL - 13

SP - 1488

EP - 1492

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 12

ER -